No FDA-approved hantavirus vaccine is expected in 2026, as no candidates have reached Phase 3 trials and most mRNA or DNA platforms targeting orthohantavirus glycoproteins remain in preclinical animal models or early Phase 1 safety testing. A May 2026 Andes virus outbreak on a cruise ship prompted modest funding increases and surveillance attention from agencies like WHO and CDC, yet low disease incidence continues to constrain large-scale efficacy studies. Full licensure typically requires multi-year human trials with clear endpoints for hantavirus pulmonary syndrome or hemorrhagic fever with renal syndrome, making accelerated approval unlikely absent unprecedented regulatory shifts. Trader consensus at 94.5% reflects these established development barriers.